https://www.selleckchem.com/pr....oducts/d-galactose.h
Standard physiologic assessments of extubation readiness in patients with acute hypoxemic respiratory failure (AHRF) may not reflect lung injury resolution and could adversely affect clinical decision-making and patient outcomes. We hypothesized that elevations in inflammatory plasma biomarkers soluble suppression of tumerogenicity-2 (sST2) and interleukin-6 (IL-6) indicate ongoing lung injury in AHRF and better inform patient outcomes compared to standard clinical assessments. We measured daily plasma biomarkers and physiologic var
Curtir
Comentario
Compartilhar
